Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.24/7 Wall Street • 5h
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View RaisedZacks Investment Research • Thursday
Incyte Reports Third Quarter 2026 Financial Results and Provides Business UpdatesBusiness Wire • Thursday
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs TranscriptSeeking Alpha • Tuesday
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyZacks Investment Research • Monday
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026Business Wire • Monday
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerBusiness Wire • 10/24/26
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal CancerBusiness Wire • 10/24/26
Analysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/22/26
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026Business Wire • 10/18/26
Incyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) CommunityBusiness Wire • 10/13/26
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans ProgressivaBusiness Wire • 09/25/26